Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
Recruitment status was Active, not recruiting
|First Received Date ICMJE||November 1, 1999|
|Last Updated Date||January 20, 2011|
|Start Date ICMJE||June 1998|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures ICMJE||Not Provided|
|Original Primary Outcome Measures ICMJE||Not Provided|
|Change History||Complete list of historical versions of study NCT00003650 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma|
|Official Title ICMJE||Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma|
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase III trial to study the effectiveness of combination chemotherapy in treating children who have non-Hodgkin's lymphoma.
OUTLINE: This is a multicenter study.
Patients receive 5 weeks of induction chemotherapy consisting of prednisone IV twice a day on days 1-28, then decreasing in dose on days 29-35; vincristine IV on days 8, 15, 22, and 29; cyclophosphamide IV over 1 hour on day 8; daunorubicin IV over 24 hours on days 15, 22, and 29; asparaginase IV or IM on days 16, 18, 20, 23, 25, 27, 30, and 32; and methotrexate IV over 3 hours on day 8. Patients also receive methotrexate and methylprednisolone intrathecally (IT) on days 1, 4, 9, and 15.
Patients with a response over 50% proceed to 4-8 weeks of consolidation therapy. This regimen consists of vincristine IV on day 15, cyclophosphamide IV over 1 hour followed by methotrexate over 3 hours on day 1, cytarabine IV on days 2-5 and 8-11, asparaginase IV or IM on days 16 and 23, and methotrexate IV over 3 hours on day 15. Patients also receive methotrexate and methylprednisolone IT on days 2 and 16. Patients who achieve complete remission after 4 weeks repeat consolidation therapy for another course.
Patients then receive 4 weeks of interphase therapy consisting of oral mercaptopurine on days 1 and 22, methotrexate IV over 3 hours on days 1 and 15, and methotrexate and methylprednisolone IT on days 2 and 16.
Patients with pre-B cell lymphoma then proceed to maintenance therapy. Patients with T cell lymphoma proceed to reinduction therapy. Reinduction A is a 4 week course of chemotherapy administered during months 1, 3, and 5 and consists of vincristine IV on day 1; methotrexate IV over 3 hours on days 1, 8, 15, and 22; methotrexate and methylprednisolone IT on day 2; asparaginase IM or IV on day 2; and oral mercaptopurine. Reinduction B is also a 4 week course of therapy administered during months 2, 4, and 6. This consists of oral prednisone twice a day on days 1-5; cytarabine subcutaneously twice a day on days 1-4; methotrexate IV on days 1, 8, 15, and 22; and oral mercaptopurine.
Patients then proceed to maintenance therapy, which consists of methotrexate and mercaptopurine once a week. Patients with stage I, II, or III disease continue maintenance therapy for 18 months, while patients with stage IV disease continue this therapy for 24 months.
Patients with stage IV disease with neuromeningeal involvement receive triple intrathecal therapy consisting of methotrexate, cytarabine, and methylprednisolone, then reinduction A for months 1, 2, and 3, then reinduction B for months 4, 5, and 6 (if T cell lymphoma). These patients also receive cerebral irradiation during months 4 and 5. Patients with pre-B cell disease receive cerebral irradiation after intensification therapy.
Patients with less than 50% response after induction therapy or incomplete remission after 4-8 weeks of consolidation therapy, or who have a recurrence of disease are treated with the "VANDA" regimen consisting of dexamethasone on days 1-5; cytarabine over 3 hours twice a day on days 1 and 2; mitoxantrone IV over 1 hour on days 3 and 4; etoposide IV over 1 hour on days 3-5; and asparaginase IV over 1 hour or IM on days 7, 9, 11, and 13. Patients also receive triple intrathecal therapy (methotrexate, cytarabine, and methylprednisolone) on day 5.
Patients are followed every 2 months for 1 year, every 3 months for 2 years, every 4 months for 1 year, every 6 months for 1 year, then annually thereafter.
PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study within 4 years.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 3|
|Study Design ICMJE||Primary Purpose: Treatment|
|Study Arm (s)||Not Provided|
|Publications *||Ducassou S, Ferlay C, Bergeron C, Girard S, Laureys G, Pacquement H, Plantaz D, Lutz P, Vannier JP, Uyttebroeck A, Bertrand Y. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br J Haematol. 2011 Jan 7; [Epub ahead of print]|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Active, not recruiting|
|Estimated Enrollment ICMJE||200|
|Completion Date||Not Provided|
|Primary Completion Date||Not Provided|
|Eligibility Criteria ICMJE||
PRIOR CONCURRENT THERAPY:
|Ages||up to 18 Years|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Location Countries ICMJE||France|
|NCT Number ICMJE||NCT00003650|
|Other Study ID Numbers ICMJE||CDR0000066742, FNCLCC-SFOP-96006-LMT-96, EU-98049|
|Has Data Monitoring Committee||Not Provided|
|Responsible Party||Not Provided|
|Study Sponsor ICMJE||UNICANCER|
|Collaborators ICMJE||Not Provided|
|Information Provided By||National Cancer Institute (NCI)|
|Verification Date||March 2001|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP